Analysts Issue Forecasts for MediWound Ltd.’s Q3 2018 Earnings (MDWD)
MediWound Ltd. (NASDAQ:MDWD) – Oppenheimer Holdings issued their Q3 2018 EPS estimates for shares of MediWound in a research report issued on Monday. Oppenheimer Holdings analyst J. Olson forecasts that the biopharmaceutical company will post earnings per share of ($0.12) for the quarter. Oppenheimer Holdings currently has a “Buy” rating and a $10.00 target price on the stock.
Several other brokerages have also recently weighed in on MDWD. SunTrust Banks, Inc. reaffirmed a “buy” rating on shares of MediWound in a research note on Monday, June 26th. Aegis reaffirmed a “buy” rating and set a $11.00 target price on shares of MediWound in a research note on Thursday, May 25th. Zacks Investment Research raised MediWound from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 2nd. Finally, Jefferies Group LLC set a $10.00 target price on MediWound and gave the company a “buy” rating in a research note on Friday, August 25th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $9.19.
COPYRIGHT VIOLATION WARNING: “Analysts Issue Forecasts for MediWound Ltd.’s Q3 2018 Earnings (MDWD)” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another site, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this story can be accessed at https://www.thecerbatgem.com/2017/09/21/analysts-issue-forecasts-for-mediwound-ltd-s-q3-2018-earnings-mdwd.html.
MediWound (NASDAQ:MDWD) traded up 1.00% on Tuesday, hitting $5.05. The stock had a trading volume of 32,538 shares. MediWound has a one year low of $4.25 and a one year high of $8.58. The company’s market cap is $110.87 million. The stock has a 50-day moving average of $6.30 and a 200-day moving average of $6.53.
MediWound (NASDAQ:MDWD) last released its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.01). The firm had revenue of $0.69 million for the quarter, compared to analyst estimates of $0.69 million. MediWound had a negative return on equity of 326.32% and a negative net margin of 752.78%. The company’s quarterly revenue was up 93.8% compared to the same quarter last year. During the same period last year, the firm earned ($0.34) EPS.
Several hedge funds and other institutional investors have recently made changes to their positions in MDWD. Migdal Insurance & Financial Holdings Ltd. lifted its holdings in shares of MediWound by 20.3% during the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 2,028,112 shares of the biopharmaceutical company’s stock valued at $13,791,000 after purchasing an additional 342,165 shares during the last quarter. Wellington Management Group LLP lifted its holdings in shares of MediWound by 11.0% during the first quarter. Wellington Management Group LLP now owns 2,157,839 shares of the biopharmaceutical company’s stock valued at $14,241,000 after purchasing an additional 213,745 shares during the last quarter. Wells Fargo & Company MN lifted its holdings in shares of MediWound by 23.5% during the second quarter. Wells Fargo & Company MN now owns 65,763 shares of the biopharmaceutical company’s stock valued at $447,000 after purchasing an additional 12,522 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in shares of MediWound by 1.7% during the first quarter. Renaissance Technologies LLC now owns 75,600 shares of the biopharmaceutical company’s stock valued at $499,000 after purchasing an additional 1,300 shares during the last quarter. 23.47% of the stock is owned by institutional investors and hedge funds.
MediWound Company Profile
MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns.
Receive News & Stock Ratings for MediWound Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound Ltd. and related stocks with our FREE daily email newsletter.